Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The incidence and mortality of anal squamous cell carcinoma (ASCC) are rising, with greater than 80% of cases linked to human papillomavirus (HPV), primarily HPV16. Post-treatment surveillance can be challenging due to the limitations of anoscopy, digital anal rectal exam (DARE), and imaging. Plasma tumor tissue modified viral (TTMV)-HPV DNA has shown strong sensitivity, specificity, and predictive value in detecting the recurrence of HPV-driven oropharyngeal cancer. Here, we investigate the ability of TTMV-HPV DNA for the early recurrence detection of ASCC. METHODS: This retrospective clinical case series included 117 patients with HPV-driven ASCC across 7 U.S. centers, monitored with TTMV-HPV DNA during routine clinical care between March 2020 and June 2024. Physician-reported clinical data and biomarker testing data were combined to create a comprehensive, longitudinal dataset for evaluating test performance metrics. RESULTS: Patients had a median age of 63 years and median post-diagnosis follow-up of 19 months. HPV status was primarily confirmed by TTMV-HPV DNA (52%) or p16 immunohistochemistry (39%). Of those tested for TTMV-HPV DNA pretreatment, 85% had a positive result. TTMV-HPV DNA clearance during or within three months post-treatment was associated with significantly better recurrence-free survival. The per-patient surveillance sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 82.8%, 98.4%, 96.0%, and 92.5%. Of 24 patients with a documented recurrence and a positive TTMV-HPV DNA test, the test was the first evidence of recurrence in 14 patients (58.3%), with a median lead time of 59 days (range: 10-536). TTMV-HPV DNA accurately resolved 94.3% of cases with indeterminate clinical findings. CONCLUSIONS: TTMV-HPV DNA testing provides a sensitive and specific approach for detecting patients with recurrent ASCC and resolving the status of patients with indeterminate clinical findings.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence
- Date Crossref
- 08/01/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Montefiore Medical Center pays non établi dans la noticeÉtablissement de santé
-
University of Utah Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Cancer Care Northwest pays non établi dans la noticeÉtablissement de santé
-
Mayo Clinic in Florida Department of Radiation Oncology pays non établi dans la noticeÉtablissement de santé
-
Freeman Health System pays non établi dans la noticeOrganisation à but non lucratif
-
Mission Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Chicago Department of Radiation and Cellular Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Inc. Naveris pays non établi dans la noticeEntreprise
-
Freeman Radiation Oncology pays non établi dans la noticeInstitution
Montefiore Medical Center, Department of Radiation Oncology — University of Utah et Cancer Care Northwest, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.